Common variable immunodeficiency
MONDO:0015517Common variable immunodeficiency (CVID) comprises a heterogeneous group of diseases characterized by a significant hypogammaglobulinemia of unknown cause, failure to produce specific antibodies after immunizations and susceptibility to bacterial infections, predominantly caused by encapsulated bacteria.
Also known as: Common Variable Immune Deficiency, idiopathic immunoglobulin deficiency, primary antibody deficiency, primary hypogammaglobulinemia, secondary hypogammaglobulinemia, Immunoglobulin deficiency, late-onset, acquired agammaglobulinemia, acquired hypogammaglobulinemia
68 clinical trials for this condition and its sub-types, 29 tagged with Common variable immunodeficiency itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Common variable immunodeficiency
-
Immune deficiency, familial variable 0 trials
-
Immunodeficiency, common variable, 1 0 trials
-
1 sub-type
-
Immunodeficiency, common variable, 2 0 trials
-
Immunodeficiency, common variable, 3 0 trials
-
Immunodeficiency, common variable, 4 0 trials
-
Immunodeficiency, common variable, 5 0 trials
-
Immunodeficiency, common variable, 6 0 trials
-
Immunodeficiency, common variable, 7 0 trials
-
Can a weekly shot bring antibody levels to safety in untreated immune deficiency?
Disease control Not yet recruitingThis trial tests whether TAK-664, an antibody replacement given under the skin, can quickly raise and maintain protective IgG levels in people with primary immunodeficiency who have never received antibody therapy. Participants receive daily doses for 5 days, then a dose on day 8…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New IVIG aims to slash infection risk for immune-deficient patients
Disease control Not yet recruitingThis study tests a new medicine called Boya IVIG in 50 people with primary immunodeficiency (CVID or XLA), a condition where the body can't fight infections well. Participants get the drug every 21 or 28 days for a year to see if it keeps serious bacterial infections below one pe…
Phase 3 • Sponsor: Azidus Brasil • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC